Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.

Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.

2.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart LJ, Van Etten RA, Flynn DL.

Cancer Cell. 2011 Apr 12;19(4):556-68. doi: 10.1016/j.ccr.2011.03.003.

3.

Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib.

Gaillard JB, Arnould C, Bravo S, Donadio D, Exbrayat C, Jourdan E, Reboul D, Chiesa J, Lavabre-Bertrand T.

Mol Cancer Ther. 2010 Nov;9(11):3083-9. doi: 10.1158/1535-7163.MCT-10-0595. Epub 2010 Nov 2.

4.

Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue - letter.

Khorashad JS, Milojkovic D, Reid AG.

Mol Cancer Ther. 2010 Jul;9(7):2152. doi: 10.1158/1535-7163.MCT-10-0311. Epub 2010 Jun 22. No abstract available.

5.

Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.

Mahadeo KM, Cole PD.

Blood. 2010 May 6;115(18):3852. doi: 10.1182/blood-2010-02-269233. No abstract available. Erratum in: Blood. 2010 Aug 12;116(6):1017.

6.

ABL alternative splicing is quite frequent in normal population - letter.

Santamaria I, Pitiot AS, Balbin M.

Mol Cancer Ther. 2010 Mar;9(3):772; author reply 772. doi: 10.1158/1535-7163.MCT-09-0078. Epub 2010 Mar 2. No abstract available.

7.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.

Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.

8.

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.

Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM.

Leukemia. 2009 Jul;23(7):1345-8. doi: 10.1038/leu.2009.66. Epub 2009 Apr 2. No abstract available.

PMID:
19340004
9.

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M.

Acta Haematol. 2009;121(1):27-31. doi: 10.1159/000210060. Epub 2009 Mar 31. Review. No abstract available.

10.

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.

Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M.

Mol Cancer Ther. 2008 Dec;7(12):3834-41. doi: 10.1158/1535-7163.MCT-08-0482. Epub 2008 Dec 3.

11.

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.

Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW.

Leukemia. 2008 Jun;22(6):1184-90. doi: 10.1038/leu.2008.65. Epub 2008 Mar 20.

PMID:
18354488
12.

An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.

Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD.

J Mol Diagn. 2008 Mar;10(2):177-80. doi: 10.2353/jmoldx.2008.070128. Epub 2008 Feb 14.

13.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

14.

Dasatinib in chronic myelogenous leukemia.

Chu SC, Tang JL, Li CC.

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4. No abstract available.

PMID:
16960978
15.

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J.

Mol Cell. 2006 Mar 17;21(6):787-98.

16.

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ.

Cancer Res. 2005 Jun 1;65(11):4500-5.

17.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Br├╝ggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD.

Cancer Cell. 2005 Feb;7(2):129-41. Erratum in: Cancer Cell. 2005 Apr;7(4):399. Mohammed, Azam [corrected to Azam, Mohammad].

18.

Overriding imatinib resistance with a novel ABL kinase inhibitor.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL.

Science. 2004 Jul 16;305(5682):399-401.

19.

Regulation of the c-Abl and Bcr-Abl tyrosine kinases.

Hantschel O, Superti-Furga G.

Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44. Review.

PMID:
14708008
20.

Autoinhibition of Bcr-Abl through its SH3 domain.

Smith KM, Yacobi R, Van Etten RA.

Mol Cell. 2003 Jul;12(1):27-37.

Supplemental Content

Support Center